SG11201903801YA - Pyridone compound as c-met inhibitor - Google Patents
Pyridone compound as c-met inhibitorInfo
- Publication number
- SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA
- Authority
- SG
- Singapore
- Prior art keywords
- met inhibitor
- pyridone compound
- met
- pyridone
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610954377 | 2016-10-27 | ||
PCT/CN2017/107964 WO2018077227A1 (zh) | 2016-10-27 | 2017-10-27 | 作为c-MET抑制剂的吡啶酮类化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903801YA true SG11201903801YA (en) | 2019-05-30 |
Family
ID=62024383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903801YA SG11201903801YA (en) | 2016-10-27 | 2017-10-27 | Pyridone compound as c-met inhibitor |
Country Status (28)
Country | Link |
---|---|
US (1) | US10501443B2 (ru) |
EP (1) | EP3533787B1 (ru) |
JP (1) | JP6719679B2 (ru) |
KR (1) | KR102070748B1 (ru) |
CN (1) | CN109311812B (ru) |
AU (1) | AU2017348810B2 (ru) |
BR (1) | BR112019008415B1 (ru) |
CA (1) | CA3041164C (ru) |
CO (1) | CO2019005165A2 (ru) |
DK (1) | DK3533787T3 (ru) |
EA (1) | EA038108B1 (ru) |
ES (1) | ES2835301T3 (ru) |
HR (1) | HRP20201985T1 (ru) |
HU (1) | HUE051734T2 (ru) |
IL (1) | IL266126B (ru) |
LT (1) | LT3533787T (ru) |
MX (1) | MX374439B (ru) |
MY (1) | MY189557A (ru) |
PE (1) | PE20190912A1 (ru) |
PH (1) | PH12019500875B1 (ru) |
PL (1) | PL3533787T3 (ru) |
PT (1) | PT3533787T (ru) |
RS (1) | RS61126B1 (ru) |
SG (1) | SG11201903801YA (ru) |
SI (1) | SI3533787T1 (ru) |
UA (1) | UA122737C2 (ru) |
WO (1) | WO2018077227A1 (ru) |
ZA (1) | ZA201903074B (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019206268A1 (zh) * | 2018-04-26 | 2019-10-31 | 福建广生堂药业股份有限公司 | 一种c-MET抑制剂的晶型及其盐型和制备方法 |
WO2020156453A1 (zh) * | 2019-02-01 | 2020-08-06 | 南京明德新药研发有限公司 | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 |
CN116171156A (zh) * | 2020-07-31 | 2023-05-26 | 南京明德新药研发有限公司 | 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法 |
WO2022063869A2 (en) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
US20240277711A1 (en) | 2021-06-04 | 2024-08-22 | Merck Patent Gmbh | Compounds for the treatment of glioblastoma |
WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002519A2 (en) * | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
JPWO2005085200A1 (ja) | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | ピリドン誘導体 |
JP2010519204A (ja) * | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用 |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
CN104144925A (zh) | 2011-10-17 | 2014-11-12 | 拜耳知识产权有限责任公司 | 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮 |
KR20140138984A (ko) * | 2012-03-19 | 2014-12-04 | 메르크 파텐트 게엠베하 | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 기타 항종양 화합물과의 조합 |
WO2014056566A1 (en) * | 2012-10-11 | 2014-04-17 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
SG11201704763SA (en) * | 2014-12-11 | 2017-07-28 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative |
-
2017
- 2017-10-27 UA UAA201904417A patent/UA122737C2/uk unknown
- 2017-10-27 PH PH1/2019/500875A patent/PH12019500875B1/en unknown
- 2017-10-27 BR BR112019008415-0A patent/BR112019008415B1/pt active IP Right Grant
- 2017-10-27 DK DK17864813.5T patent/DK3533787T3/da active
- 2017-10-27 MX MX2019004626A patent/MX374439B/es active IP Right Grant
- 2017-10-27 CA CA3041164A patent/CA3041164C/en active Active
- 2017-10-27 KR KR1020197014236A patent/KR102070748B1/ko active Active
- 2017-10-27 HU HUE17864813A patent/HUE051734T2/hu unknown
- 2017-10-27 WO PCT/CN2017/107964 patent/WO2018077227A1/zh active Application Filing
- 2017-10-27 MY MYPI2019002142A patent/MY189557A/en unknown
- 2017-10-27 EA EA201990952A patent/EA038108B1/ru unknown
- 2017-10-27 SI SI201730558T patent/SI3533787T1/sl unknown
- 2017-10-27 RS RS20201448A patent/RS61126B1/sr unknown
- 2017-10-27 SG SG11201903801YA patent/SG11201903801YA/en unknown
- 2017-10-27 AU AU2017348810A patent/AU2017348810B2/en active Active
- 2017-10-27 PL PL17864813T patent/PL3533787T3/pl unknown
- 2017-10-27 CN CN201780036464.XA patent/CN109311812B/zh active Active
- 2017-10-27 PT PT178648135T patent/PT3533787T/pt unknown
- 2017-10-27 PE PE2019000855A patent/PE20190912A1/es unknown
- 2017-10-27 JP JP2019540379A patent/JP6719679B2/ja active Active
- 2017-10-27 ES ES17864813T patent/ES2835301T3/es active Active
- 2017-10-27 EP EP17864813.5A patent/EP3533787B1/en active Active
- 2017-10-27 US US16/343,387 patent/US10501443B2/en active Active
- 2017-10-27 LT LTEP17864813.5T patent/LT3533787T/lt unknown
-
2019
- 2019-04-18 IL IL266126A patent/IL266126B/en active IP Right Grant
- 2019-05-16 ZA ZA2019/03074A patent/ZA201903074B/en unknown
- 2019-05-21 CO CONC2019/0005165A patent/CO2019005165A2/es unknown
-
2020
- 2020-12-10 HR HRP20201985TT patent/HRP20201985T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903801YA (en) | Pyridone compound as c-met inhibitor | |
SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
NZ729005A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
PH12016500467B1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
ZA202206923B (en) | New methylquinazolinone derivatives | |
MX2014012454A (es) | Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria. | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
PH12017501523A1 (en) | Selective bace1 inhibitors | |
MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
MY194116A (en) | Pharmaceutical compounds | |
PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
JO3318B1 (ar) | مثبطات bace | |
MX2016013265A (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
PH12016502246B1 (en) | Carboxamide derivatives | |
MX2018014813A (es) | Composiciones antibacterianas. | |
MY193239A (en) | Novel b-lactamase inhibitors | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor |